In neurocognitive disorders such as Down syndrome and Fragile X where neurogenesis is impaired, administration of GSK3β inhibitors were shown to enhance neurogenesis (Guo et al., 2012; Contestabile et al., 2013). The gene discussed is GSK3B; the disease is Down syndrome.